Breaking News

Pfizer’s Celebrex Patent Upheld

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

A federal court in the District of New Jersey (Newark) has upheld Pfizer’s three main U.S. patents covering Celebrex, a selective non-steroidal anti-inflammatory (NSAID) medicine used to treat pain and inflammation. Generic manufacturer Teva Pharmaceuticals USA had challenged the patents. Judge John C. Lifland ruled that the patents covering the active ingredient, pharmaceutical composition, and method of use for Celebrex are valid, enforceable and infringed by the generic manufacture...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters